Description

Legend Biotech: The Outpatient Advantage—A Practical Edge That Could Accelerate CARVYKTI Adoption Beyond Academic Centers!

Legend Biotech reported strong financial results for the third quarter of 2025, highlighting significant progress in its CARVYKTI program and future growth prospects in cell therapy. The company’s financial performance drew attention with net trade sales for CARVYKTI reaching approximately $524 million, marking an 84% increase year-over-year. This positioned CARVYKTI as a prominent player in the CAR-T cell therapy market, particularly for multiple myeloma, illustrating its potential to become an increasingly vital revenue stream. CARVYKTI’s approval process also hit a major milestone as the FDA approved an update to include overall survival benefits on its label. Phase III CARTITUDE-4 study data demonstrated a statistically significant improvement in overall survival compared to standard care therapies in relapsed/refractory multiple myeloma patients, further enhancing CARVYKTI’s clinical profile.